Nifedipine

Nifedipine is a calcium channel blocker, of the dihydropyridine type. The US label read is for nifedipine extended-release tablets and lists two uses: the management of vasospastic angina, and the management of chronic stable angina without evidence of vasospasm in patients who remain symptomatic despite adequate doses of beta blockers or organic nitrates, or who cannot tolerate those agents. No brand-name nifedipine label was found in openFDA, so this page rests on a generic manufacturer's label.

Also called Nifedipine extended-release tablets

  • Drug
  • In this atlas

Overview

Technical summary

RxNorm ingredient 7417; UNII I9ZF7L6G2L. MeSH descriptor D009543 is Nifedipine. Class: Dihydropyridine Calcium Channel Blocker (FDA established pharmacologic class, RxClass). The label read is the nifedipine extended-release tablets, Upsher-Smith Laboratories, LLC label, effective 2026-01-19 in openFDA (application ANDA203126). Other nifedipine labels in openFDA, from other sponsors and repackagers, were not read. This page records label indications and the class only: no trial result and no dose is given.

Trials at a glance

The figures count the 9 registry trials in this atlas that name this drug or a product that contains it. Trials that use another name for it are not counted.

Trials
9
Phase 3 or 4
9
Recruiting
1
Regulatory decisions
0
Trials by phase (rows) and registry status (columns)
PhaseRecruitingCompletedUnknown statusAll statuses
Phase 30202
Phase 41517
All phases1719

Conditions these trials study

Sponsors with the most trials

The lead sponsor of each trial, as the registry names it.

And 2 more.

About this drug

Level
Substance
Mechanism
Not reported

Claims and evidence

Context People for whom the US label of nifedipine extended-release tablets lists an indication: vasospastic angina, chronic stable angina

Recipient
Recipient not specified
Population
Patients described in the indications section of the label. The label does not state an age range in the passages read.
Care setting
Prescription medicine, as described in the US label
Geography
United States (label of the US Food and Drug Administration)
Life stage
Not stated in the label passages read
Gestational age
Not reported
Postnatal age
Not reported
Follow-up
Not applicable (label statement)
Eligibility: 2 inclusion criteria; exclusion criteria not stated
Included
  • Patients with vasospastic angina
  • Patients with chronic stable angina without evidence of vasospasm who remain symptomatic despite adequate doses of beta blockers or organic nitrates, or who cannot tolerate those agents
Excluded
None stated
  • Description Evidence stage not applicable Certainty not assessed

    The US label of nifedipine extended-release tablets, in the Upsher-Smith Laboratories, LLC version dated 2026-01-19 in openFDA, lists the medicine for the management of vasospastic angina, and for the management of chronic stable angina (effort-associated angina) without evidence of vasospasm in patients who remain symptomatic despite adequate doses of beta blockers or organic nitrates, or who cannot tolerate those agents.

    Applies to Recipient not specified People for whom the US label of nifedipine extended-release tablets lists an indication: vasospastic angina, chronic stable angina

    Certainty method
    Not assessed
    Limitations
    This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
    Last checked
    2026-11-09
    Next evidence check due
    Not scheduled
    Sources and citations (2)
    1. Supports openFDA drug label record for nifedipine extended-release tablets, Upsher-Smith Laboratories, LLC label: indications and substance identifiers

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 3bf4282f-b063-4d35-8ef0-6f48b98e9deb (manufacturer Upsher-Smith Laboratories, LLC, application ANDA203126), returned on 2026-11-09. The label text is dated 2026-01-19 (effective_time). Other openFDA records of nifedipine labels from other sponsors and repackagers exist and were not used.

      Locator
      results[0].indications_and_usage[0]
      How it applies
      The label sentences that give the indications named in the statement, each quoted in the research quote table.
      Retrieved
      Source effective date
      2026-01-19
      Source state
      Current
      Version fingerprint
      c069ea3c1e7516d4e5f12ff730186c2bc09b702825b261ac8c2355a7f2758fdf
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    2. Background openFDA drug label record for nifedipine extended-release tablets, Upsher-Smith Laboratories, LLC label: indications and substance identifiers

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 3bf4282f-b063-4d35-8ef0-6f48b98e9deb (manufacturer Upsher-Smith Laboratories, LLC, application ANDA203126), returned on 2026-11-09. The label text is dated 2026-01-19 (effective_time). Other openFDA records of nifedipine labels from other sponsors and repackagers exist and were not used.

      Locator
      results[0].effective_time
      How it applies
      Effective date of the label text read, 20260119.
      Retrieved
      Source effective date
      2026-01-19
      Source state
      Current
      Version fingerprint
      c069ea3c1e7516d4e5f12ff730186c2bc09b702825b261ac8c2355a7f2758fdf
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.

FDA label

The FDA label of the application holder, as the openFDA label dataset holds it, for the products that contain this drug.

ADALAT

No label from the application holder was found in the openFDA label dataset for application NDA019478. This page does not show another labeler's label in its place.

ADALAT CC

No label from the application holder was found in the openFDA label dataset for application NDA020198. This page does not show another labeler's label in its place.

PROCARDIA

No label from the application holder was found in the openFDA label dataset for application NDA018482. This page does not show another labeler's label in its place.

PROCARDIA XL

No label from the application holder was found in the openFDA label dataset for application NDA019684. This page does not show another labeler's label in its place.

FDA decisions timeline

The regulatory decisions of the FDA that this atlas holds for this drug and the products that contain it, oldest first. Each links to its full record.

  1. Approval NDA018482 PROCARDIA
  2. Supplemental approval NDA018482 PROCARDIA
  3. Approval NDA019478 ADALAT
  4. Supplemental approval NDA018482 PROCARDIA
  5. Approval NDA019684 PROCARDIA XL
  6. Approval NDA020198 ADALAT CC

Clinical links

Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.

Registry records

Assembled by a program from ClinicalTrials.gov and openFDA. No person wrote or checked these pages, and they are counted apart from the pages that people wrote. Lists of trials come from the registry's own coding and may miss trials.

Registry products 4

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and 2 efficacy supplement approvals on record.

    ProductNDA018482

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.

    ProductNDA019478

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.

    ProductNDA019684

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.

    ProductNDA020198

Registry trials 9

Record details

Record id
cardio:nifedipine
Content hash
bb9b665dc477357852bb7e7137490499e0a32d6b236c06984cd2b31afcac7667